Catheter Port Reversal in Citrate Continuous Veno-Venous Hemofiltration

被引:3
|
作者
Boer, Willem [1 ]
Van Tornout, Mathias [2 ]
Vander Laenen, Margot [1 ]
Engelen, Kim [1 ]
Meex, Ingrid [1 ]
Jorens, Philippe [3 ]
机构
[1] Ziekenhuis Oost Limburg ZOL, Dept Anesthesiol Intens Care Med Emergency Med &, Schiepsebos 6, B-3600 Genk, Belgium
[2] AZ Sint Jan Brugge Oostende AV, Dept Anesthesiol & Intens Care Med, Brugge, Belgium
[3] Univ Antwerp, Antwerp Univ Hosp, Dept Crit Care Med, LEMP, Edegem, Belgium
来源
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 11期
关键词
access recirculation; catheter dysfunction; continuous renal replacement therapy; regional citrate anticoagulation; ACCESS RECIRCULATION; HEMODIALYSIS;
D O I
10.1016/j.ekir.2021.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Knowledge of effects of catheter port reversal (CathPR), when blood is withdrawn from the venous port and returned via the arterial port, often used in dysfunctional catheters in renal replacement therapy, is limited in the setting of citrate continuous veno-venous hemofiltration (CVVH). Methods: In this open trial, post-filter ionized calcium (PfiCa), post-filter citrate concentration (PfCC), catheter recirculation, and solute clearance were measured before, during, and after 6 hours of CathPR, in well-functioning catheters. All other settings, including citrate settings, were left constant during the study. Results: Twenty-three patients were included. Mean PfiCa before CathPR of 0.36 mmol/L (SD 0.06) decreased to 0.31 (0.04) after 2 hours (P = 0.002), 0.31 (0.04) (P = 0.002) at 4 hours, and 0.31 (0.04) at 6 hours (P = 0.001). Return to normal increased mean PfiCa to 0.34 (0.06) (P = 0.006). Mean PfCC rose from 592 mg/L (SD 164) before CathPR to 649 mg/L (190) after 2 hours (P = 0.045), to 696 mg/L (192) after 4 hours (P < 0.001), and to 657 mg/L (214) after 6 hours (P = 0.018). Return to normal decreased mean PfCC to 598 mg/L (184) (P = 0.024). Mean recirculation increased during CathPR (from 4.3% [0-8.7] before to 13.8% [9.7-22.2], P < 0.001). Urea, potassium, and creatinine clearances dropped significantly, but calcium clearance was unaffected. Conclusion: CathPR caused a significant decrease in PfiCA and increase in PfCC. Calcium handling differs from other solutes because of increases caused in citrate concentration and subsequent effects on calcium chelation. In citrate CVVH, CathPR in dysfunctional catheters should be limited in time, with intensive follow-up.
引用
收藏
页码:2775 / 2781
页数:7
相关论文
共 50 条
  • [31] Successful treatment of extreme hypernatremia by continuous veno-venous hemodiafiltration
    Giabicani, Mikhael
    Guitard, Pierre-Gildas
    Guerrot, Dominique
    Grange, Steven
    Teule, Lauranne
    Dureuil, Bertrand
    Veber, Benoit
    NEPHROLOGIE & THERAPEUTIQUE, 2015, 11 (06): : 492 - 495
  • [32] Elimination Rates of Electrolytes, Vitamins, and Trace Elements during Continuous Renal Replacement Therapy with Citrate Continuous Veno-Venous Hemodialysis: Influence of Filter Lifetime
    Datzmann, Thomas
    Traeger, Karl
    Reinelt, Helmut
    von Freyberg, Philipp
    BLOOD PURIFICATION, 2017, 44 (03) : 210 - 216
  • [33] The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration
    Opatrny, K
    Polanská, K
    Krouzecky, A
    Novák, I
    Kasal, E
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2002, 25 (06) : 520 - 528
  • [34] Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration
    Wallis, SC
    Mullany, DV
    Lipman, J
    Rickard, CM
    Daley, PJ
    INTENSIVE CARE MEDICINE, 2001, 27 (04) : 665 - 672
  • [35] Continuous Veno-Venous High Cut-Off Hemodialysis Compared to Continuous Veno-Venous Hemodiafiltration in Intensive Care Unit Acute Kidney Injury Patients
    Balgobin, Sanjeet
    Morena, Marion
    Brunot, Vincent
    Besnard, Noemie
    Daubin, Delphine
    Platon, Laura
    Larcher, Romaric
    Amigues, Laurent
    Landreau, Liliane
    Bargnoux, Anne-Sophie
    Dupuy, Anne-Marie
    Cristol, Jean-Paul
    Klouche, Kada
    BLOOD PURIFICATION, 2018, 46 (03) : 248 - 256
  • [36] Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose
    Chiew, A. L.
    Khamoudes, D.
    Chan, B. S. H.
    CLINICAL TOXICOLOGY, 2014, 52 (04) : 283 - 287
  • [37] Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report
    Williams, Kelsey N.
    Bidell, Monique R.
    Adamsick, Meagan L.
    Elshaboury, Ramy H.
    Roberts, Matthew B.
    Kotton, Camille N.
    Gandhi, Ronak G.
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [38] Impact of continuous veno-venous hemodiafiltration with regional citrate anticoagulation on the acid-base balance of critically ill patients
    RH Passos
    MB Ferri
    N Akamine
    MC Batista
    JCM Monte
    BFC Santos
    VG Pereira
    MS Durao
    OFP Santos
    Critical Care, 10 (Suppl 1):
  • [39] Continuous veno-venous hemodiafiltration in neonates with maple syrup urine disease
    Deger, Ibrahim
    celik, Muhittin
    Tas, Ibrahim
    Samanci, Serhat
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (03) : 658 - 666
  • [40] Low Blood Flow Continuous Veno-Venous Haemodialysis Compared with Higher Blood Flow Continuous Veno-Venous Haemodiafiltration: Effect on Alarm Rates, Filter Life, and Azotaemic Control
    Sansom, Benjamin
    Sriram, Shyamala
    Presneill, Jeffrey
    Bellomo, Rinaldo
    BLOOD PURIFICATION, 2022, 51 (02) : 130 - 137